According to analysts at Fortune Business Insights, two-thirds of these centers are owned by one of three companies: CSL Plasma, Grifols, and BioLife. Even before the pandemic hit, global demand ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

Australian biopharmaceutical company CSL reported a drop in vaccine sales due to falling immunization rates in the U.S., its largest market. The decline contributed to lower-than-expected profits, ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...